Tymazoline
Identification
- Name
- Tymazoline
- Accession Number
- DB08803
- Description
Tymazoline is a nasal preparation.
- Type
- Small Molecule
- Groups
- Experimental
- Structure
- Weight
- Average: 232.3214
Monoisotopic: 232.157563272 - Chemical Formula
- C14H20N2O
- Synonyms
- Tymazoline
Pharmacology
- Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:Accelerate your drug discovery research with our fully connected ADMET dataset
- Indication
For the treatment of Inflammation of the lining of the nose and paranasal sinuses and allergic inflammation of nasopharyngeal.
- Contraindications & Blackbox Warnings
- Contraindications & Blackbox WarningsWith our commercial data, access important information on dangerous risks, contraindications, and adverse effects.Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
- Pharmacodynamics
Tymazoline is a drug with antihistaminic and sympathomimetic properties. It locally reduces swelling, inflammation and mucosal secretions of the nasal passages.
- Mechanism of action
Thymazen causes vasoconstriction of the nasal mucosa, reducing congestion and thus the swelling of the mucosa. Also reduces the secretions from the nose. Thymazen acts on alpha-adrenergic receptors, which reduces local inflammation of the nasal mucosa especially if their cause is an allergy.
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
- Reduce medical errorsand improve treatment outcomes with our comprehensive & structured data on drug adverse effects.Reduce medical errors & improve treatment outcomes with our adverse effects data
- Toxicity
A large overdose or accidental oral intake, especially in children, may cause excessive sedation with drowsiness, reduced body temperature, heart rate relief and fluctuations in blood pressure and collapse.
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareOxymetazoline The absorption of Tymazoline can be decreased when combined with Oxymetazoline. Improve patient outcomesBuild effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.Learn more - Food Interactions
- Not Available
Products
- Comprehensive & structured drug product infoFrom application numbers to product codes, connect different identifiers through our commercial datasets.Easily connect various identifiers back to our datasets
- International/Other Brands
- Thymazen
Categories
- ATC Codes
- R01AA13 — Tymazoline
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as aromatic monoterpenoids. These are monoterpenoids containing at least one aromatic ring.
- Kingdom
- Organic compounds
- Super Class
- Lipids and lipid-like molecules
- Class
- Prenol lipids
- Sub Class
- Monoterpenoids
- Direct Parent
- Aromatic monoterpenoids
- Alternative Parents
- Monocyclic monoterpenoids / Phenylpropanes / Cumenes / Phenoxy compounds / Phenol ethers / Toluenes / Alkyl aryl ethers / Imidolactams / Imidazolines / Propargyl-type 1,3-dipolar organic compounds show 5 more
- Substituents
- 2-imidazoline / Alkyl aryl ether / Amidine / Aromatic heteromonocyclic compound / Aromatic monoterpenoid / Azacycle / Benzenoid / Carboximidamide / Carboxylic acid amidine / Cumene show 18 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- Not Available
Chemical Identifiers
- UNII
- U993RH5585
- CAS number
- 24243-97-8
- InChI Key
- QRORCRWSRPKEHR-UHFFFAOYSA-N
- InChI
- InChI=1S/C14H20N2O/c1-10(2)12-5-4-11(3)8-13(12)17-9-14-15-6-7-16-14/h4-5,8,10H,6-7,9H2,1-3H3,(H,15,16)
- IUPAC Name
- 2-[5-methyl-2-(propan-2-yl)phenoxymethyl]-4,5-dihydro-1H-imidazole
- SMILES
- CC(C)C1=C(OCC2=NCCN2)C=C(C)C=C1
References
- General References
- Levrier J, Molon-Noblot S, Duval D, Lloyd KG: A new ex vivo method for the study of nasal drops on ciliary function. Fundam Clin Pharmacol. 1989;3(5):471-82. [PubMed:2481638]
- Lorino AM, Lofaso F, Drogou I, Abi-Nader F, Dahan E, Coste A, Lorino H: Effects of different mechanical treatments on nasal resistance assessed by rhinometry. Chest. 1998 Jul;114(1):166-70. [PubMed:9674465]
- External Links
- Human Metabolome Database
- HMDB0015693
- KEGG Drug
- D07373
- PubChem Compound
- 34154
- PubChem Substance
- 99445273
- ChemSpider
- 31478
- ChEBI
- 134947
- ChEMBL
- CHEMBL2106467
- ZINC
- ZINC000000002232
- PharmGKB
- PA165958422
- Wikipedia
- Tymazoline
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.118 mg/mL ALOGPS logP 3.2 ALOGPS logP 2.64 ChemAxon logS -3.3 ALOGPS pKa (Strongest Basic) 7.66 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 3 ChemAxon Hydrogen Donor Count 1 ChemAxon Polar Surface Area 33.62 Å2 ChemAxon Rotatable Bond Count 4 ChemAxon Refractivity 69.54 m3·mol-1 ChemAxon Polarizability 27.29 Å3 ChemAxon Number of Rings 2 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule Yes ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.9947 Blood Brain Barrier - 0.572 Caco-2 permeable - 0.5359 P-glycoprotein substrate Substrate 0.7787 P-glycoprotein inhibitor I Non-inhibitor 0.8564 P-glycoprotein inhibitor II Non-inhibitor 0.588 Renal organic cation transporter Inhibitor 0.6599 CYP450 2C9 substrate Non-substrate 0.7725 CYP450 2D6 substrate Non-substrate 0.5833 CYP450 3A4 substrate Non-substrate 0.5478 CYP450 1A2 substrate Inhibitor 0.653 CYP450 2C9 inhibitor Non-inhibitor 0.8779 CYP450 2D6 inhibitor Inhibitor 0.8674 CYP450 2C19 inhibitor Non-inhibitor 0.8289 CYP450 3A4 inhibitor Non-inhibitor 0.8562 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.6477 Ames test Non AMES toxic 0.78 Carcinogenicity Non-carcinogens 0.9076 Biodegradation Not ready biodegradable 0.9959 Rat acute toxicity 3.2336 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.5936 hERG inhibition (predictor II) Non-inhibitor 0.6603
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Drug created on October 15, 2010 16:48 / Updated on June 12, 2020 16:52